*** CHEMICAL IDENTIFICATION *** RTECS NUMBER : NJ5758500 CHEMICAL NAME : Imidazo(1,2-a)pyridine, 2-(p-(methylsulfonyl)phenyl)- CAS REGISTRY NUMBER : 1222-57-7 BEILSTEIN REFERENCE NO. : 0752451 REFERENCE : 5-23-12-00328 (Beilstein Handbook Reference) LAST UPDATED : 199712 DATA ITEMS CITED : 4 MOLECULAR FORMULA : C14-H12-N2-O2-S MOLECULAR WEIGHT : 272.34 WISWESSER LINE NOTATION : T56 AN DNJ CR DSW1 COMPOUND DESCRIPTOR : Drug SYNONYMS/TRADE NAMES : * Imidazo(1,2-a)pyridine, 2-(4-(methylsulfonyl)phenyl)- * 2-(4-(Methylsulfonyl)phenyl)imidazo(1,2-a)pyridine * Solimidin * Zolimidin * Zolimidine * Zoliridine *** HEALTH HAZARD DATA *** ** ACUTE TOXICITY DATA ** TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3710 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #3318880 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 950 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 33,1655,1983 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4400 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : FMXXAJ French Medicament Patent Document. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Discontinued. Volume(issue)/page/year: #8177M TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 765 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : FMXXAJ French Medicament Patent Document. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Discontinued. Volume(issue)/page/year: #8177M *** END OF RECORD ***